Litcius/Paper detail

Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways

Songnan Li, Jingrui Zhang, Lu Zhou, Hui Xi, Changyi Li, Lei Zhao

2021Journal of Cardiovascular Translational Research38 citationsDOI

Topics & Concepts

ValsartanAngiotensin IIAtrial fibrillationMedicineFibrosisInternal medicineCardiologyAngiotensin receptorAtrial natriuretic peptideAngiotensin II receptor type 1Cardiac fibrosisMyocardial infarctionSacubitrilEndocrinologyReceptorBlood pressureAtrial Fibrillation Management and OutcomesCardiac Fibrosis and RemodelingCardiac electrophysiology and arrhythmias
Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways | Litcius